<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01748838</url>
  </required_header>
  <id_info>
    <org_study_id>CTX-4430-HV-001</org_study_id>
    <nct_id>NCT01748838</nct_id>
  </id_info>
  <brief_title>Phase 1 Study Assessing the Safety and Tolerability of CTX-4430</brief_title>
  <official_title>A Phase I Randomised, Double-Blind, Placebo-Controlled, Ascending Single &amp; Repeat-Dose Study of Safety, Tolerability &amp; Pharmacokinetics of CTX-4430 When Administered Orally to Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celtaxsys, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinical Network Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Linear Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>CPR Pharma Services Pty Ltd, Australia</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Celtaxsys, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of CTX-4430 capsules taken&#xD;
      orally once daily in normal healthy volunteers. CTX-4430 is being developed to treat lung&#xD;
      inflammation that occurs in cystic fibrosis (CF). This study includes two-parts: Part 1&#xD;
      assesses single dosing; and Part 2 assesses repeat dosing for 14 days. Each part will include&#xD;
      several dosages. During the single-dose part of the study, following a 14-day washout period,&#xD;
      two cohorts will be assessed for potential effects on tolerability when fed at the time of&#xD;
      dosing. For both parts of the study, blood samples will be collected for PK assay validation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of CTX-4430 in healthy subjects by evaluating changes in physical exams, laboratory tests, vital signs (e.g., blood pressure), pulmonary function tests, ECGs, and the occurrence and severity of adverse events.</measure>
    <time_frame>16 days</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Pulmonary Inflammation</condition>
  <arm_group>
    <arm_group_label>Part 1: CTX-4430</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Placebo + Mannitol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: CTX-4430</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Placebo + Mannitol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTX-4430</intervention_name>
    <description>Ascending single oral doses of CTX-4430 will be administered to subjects in 6 cohorts on day 1. Following a 14-day washout, subjects in two of the six cohorts will cross-over, fed a high fat diet and administered different single oral doses of CTX-4430</description>
    <arm_group_label>Part 1: CTX-4430</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mannitol</intervention_name>
    <description>excipient blended with CTX-4430 in capsules</description>
    <arm_group_label>Part 1: CTX-4430</arm_group_label>
    <arm_group_label>Part 1: Placebo + Mannitol</arm_group_label>
    <other_name>osmitrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single oral doses of placebo will be administered to subjects in 6 cohorts on day 1. Following a 14-day washout, subjects in two of the six cohorts will cross over, fed a high fat diet and administered single oral doses of placebo</description>
    <arm_group_label>Part 1: Placebo + Mannitol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTX-4430</intervention_name>
    <description>Ascending repeat doses of CTX-4430 will be administered orally, once-daily, to subjects in 4 cohorts on days 1-14.</description>
    <arm_group_label>Part 2: CTX-4430</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Repeat doses of placebo will be administered orally, once-daily, to subjects in 4 cohorts on days 1-14.</description>
    <arm_group_label>Part 2: Placebo + Mannitol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mannitol</intervention_name>
    <description>excipient blended with CTX-4430</description>
    <arm_group_label>Part 2: CTX-4430</arm_group_label>
    <arm_group_label>Part 2: Placebo + Mannitol</arm_group_label>
    <other_name>osmitrol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and females, 18 to 55 years of age&#xD;
&#xD;
          -  Medically healthy&#xD;
&#xD;
          -  Body mass index ≥ 18.0 and ≤ 29.9&#xD;
&#xD;
          -  Non-tobacco/nicotine-containing product users 6 months prior to the first study drug&#xD;
             administration&#xD;
&#xD;
          -  Negative urine drug/alcohol screen prior to Day -1&#xD;
&#xD;
          -  Voluntary consent&#xD;
&#xD;
          -  Male agrees to be sexually abstinent or to use a condom when engaging in sexual&#xD;
             activity through completion&#xD;
&#xD;
          -  Females of childbearing potential must either be sexually inactive for 14 days prior&#xD;
             to the first study drug administration and remain so through 30 days following the&#xD;
             final dosing of the study drug, or have been using one of the following methods of&#xD;
             birth control for the times specified:&#xD;
&#xD;
          -  Intra-uterine device in place for at least 3 months prior&#xD;
&#xD;
          -  Double barrier method for at least 14 days prior&#xD;
&#xD;
          -  Male partner who is surgical sterile at least 6 months prior to first study drug&#xD;
             administration and is sole sexual partner for that female&#xD;
&#xD;
          -  Adequate hormonal contraception.Female subjects who become sexually active during the&#xD;
             course of the study must use a double barrier method from the start of sexual activity&#xD;
             through 30 days following the final dosing&#xD;
&#xD;
          -  Females of non-childbearing potential have undergone one of the following&#xD;
             sterilization procedures at least 6 months prior to first study drug administration:&#xD;
&#xD;
          -  Essure® sterilization and be using a barrier method throughout the study&#xD;
&#xD;
          -  bilateral tubal ligation with a barrier method throughout the study&#xD;
&#xD;
          -  hysterectomy&#xD;
&#xD;
          -  bilateral oophorectomy or be postmenopausal with amenorrhea for at least 1 year prior&#xD;
             to the first study drug administration and follicle stimulating hormone serum levels&#xD;
             ≥40 mIU/mL&#xD;
&#xD;
          -  Subject has a Forced Expiratory Volume of ≥80% of predicted at screening&#xD;
&#xD;
          -  Subject has a resting oxygen saturation &gt;92% on room air&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Positive testing for human immunodeficiency virus,hepatitis B surface antigen, or&#xD;
             hepatitis C antibodies&#xD;
&#xD;
          -  Subject is febrile at any stage from screening until pre-dose&#xD;
&#xD;
          -  History or presence of alcoholism or drug abuse within 2 years prior to the first&#xD;
             study drug administration&#xD;
&#xD;
          -  Hypersensitivity or idiosyncratic reaction to compounds related to CTX-4430.&#xD;
&#xD;
          -  Use of any over-the-counter medication,(including herbal products and vitamin&#xD;
             supplements),within the 7 days prior to the Day 1. Use of any nonsteroidal&#xD;
             anti-inflammatory drugs,aspirin,antirheumatic drugs, leukotriene receptor antagonists,&#xD;
             leukotriene enzyme inhibitors within the 14 days prior to the first study drug&#xD;
             administration or 5 half-lives,whichever is longer. Administration or use of&#xD;
             oral,inhaled, intranasal, parenteral, or &gt;1% topical glucocorticoids within the 6&#xD;
             months prior to Day 1&#xD;
&#xD;
          -  Use of any significant inhibitors or substrates of OAT3, OCT2 and/or OATP P1/B1 within&#xD;
             30 days prior to the first study drug administration&#xD;
&#xD;
          -  Blood donation or significant blood loss within 60 days prior to the first study drug&#xD;
             administration&#xD;
&#xD;
          -  Plasma donation within 7 days prior to the first study drug administration.&#xD;
&#xD;
          -  Participation in another clinical trial within 30 days prior to the first study drug&#xD;
             administration&#xD;
&#xD;
          -  Females who are pregnant or lactating&#xD;
&#xD;
          -  Clinically relevant surgery within the past three months prior to first drug&#xD;
             administration&#xD;
&#xD;
          -  Personal or family history of prolonged QT syndrome; or a QTc interval &gt;430 msec&#xD;
             (males) or &gt;450 msec (females)&#xD;
&#xD;
          -  Sitting blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg&#xD;
&#xD;
          -  Pulse is higher than 100 b.p.m.&#xD;
&#xD;
          -  Regular alcohol consumption in males &gt;21 units per week and females &gt;14 units per week&#xD;
&#xD;
          -  Failure to satisfy the PI of fitness to participate for any reason&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  History of seizure&#xD;
&#xD;
          -  History or presence of clinically significant cardiovascular, pulmonary, hepatic,&#xD;
             renal, haematological, gastrointestinal, endocrine,immunologic, dermatologic,&#xD;
             neurological, or psychiatric disease&#xD;
&#xD;
          -  Use of any prescription medication within 14 days prior to Day 1&#xD;
&#xD;
          -  Acute illness within 30 days prior to Day 1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janakan Krishnarajah, MB, BS FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Linear Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>December 8, 2012</study_first_submitted>
  <study_first_submitted_qc>December 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2012</study_first_posted>
  <last_update_submitted>September 9, 2013</last_update_submitted>
  <last_update_submitted_qc>September 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mannitol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

